1999
[123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia
Verhoeff N, Soares J, D’Souza C, Gil R, Degen K, Abi-Dargham A, Zoghbi S, Fujita M, Rajeevan N, Seibyl J, Krystal J, van Dyck C, Charney D, Innis R. [123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Research 1999, 91: 163-173. PMID: 10641580, DOI: 10.1016/s0925-4927(99)00027-x.Peer-Reviewed Original ResearchConceptsDuration of illnessHealthy control subjectsControl subjectsGamma-aminobutyric acidLeft precentral gyrusSuperior occipital gyrusPANSS scoresPrecentral gyrusOccipital gyrusSignificant differencesTotal brain uptakeNon-smoking patientsGray matter atrophyConstant infusion paradigmPathophysiology of schizophreniaCortical brain regionsSingle photon emissionTypical antipsychoticsAtypical antipsychoticsCigarette smokingInhibitory neurotransmissionBrain uptakeInfusion paradigmMatter atrophyPostmortem studies
1998
Significance of nonuniform attenuation correction in quantitative brain SPECT imaging.
Rajeevan N, Zubal IG, Ramsby SQ, Zoghbi SS, Seibyl J, Innis RB. Significance of nonuniform attenuation correction in quantitative brain SPECT imaging. Journal Of Nuclear Medicine 1998, 39: 1719-26. PMID: 9776276.Peer-Reviewed Original ResearchConceptsHealthy control subjectsHealthy human control subjectsHuman control subjectsControl subjectsDisease patientsGroup of patientsParkinson's disease patientsNonuniform attenuation correctionOutcome measuresParkinson's diseaseSPECT scansBrain SPECTBrain regionsDopamine transporterPatientsBackground activity ratioNonuniform attenuation mapGold standardModerate improvementScansBrain ROIsSPECT imagesAttenuation correctionDiseaseQuantitative brain SPECT